3 recruiting, 2 not yet recruiting. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Not yet recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Adebrelimab (SHR-1316): new trials by email Literature Review of Adebrelimab (SHR-1316) trials Research Report on Adebrelimab (SHR-1316)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab - Adebrelimab (SHR-1316), Bevacizumab | Phase 2 | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 38 | 2026-04-10 | 2026-04-28 |
| Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Adebrelimab, chemotherapy - Adebrelimab (SHR-1316), NSCLC | Phase 2 | Not yet recruiting | Zhangzhou Municipal Hospital | 32 | 2025-06-20 | 2025-06-25 |
| Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE Adebrelimab and capecitabine, capecitabine - Cholangiocarcinoma Cancer, Adebrelimab (SHR-1316) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 122 | 2024-09-20 | 2025-01-16 |
| A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) Adebrelimab, XELOX - Adebrelimab (SHR-1316), XELOX | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 25 | 2024-07-01 | 2024-07-17 |
| Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer Adebrelimab;decitabine; - Adebrelimab (SHR-1316), Decitabine | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 20 | 2024-06-15 | 2024-06-28 |
Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Pancreatic Neoplasms (1)
Neoplasms (3) · Adenocarcinoma (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Liver Diseases (1) · Liver Neoplasms (1) · Pancreatic Diseases (1)
Bevacizumab (1) · Capecitabine (1) · Drug Therapy (1) · Folfox protocol (1) · XELOX (1)
Tianjin Medical University Cancer Institute and Hospital (2) · The First Affiliated Hospital with Nanjing Medical University (1) · Third Affiliated Hospital, Sun Yat-Sen University (1) · Zhangzhou Municipal Hospital (1)
China (3)